|
2011 |
December |
Hanmi Pharmaceutical’s first shipment of ‘AMOSARTAN’ has been made to MSD |
|
|
December |
Hanmi’s ‘ORASCOVERY’ technology, licensed out to USA |
|
|
November |
Orphan drug designation for LAPS-rhGH applied |
|
|
November |
Amosartan Clinical study is published on BMC Research Note |
|
|
October |
Phase 2 study of long acting human growth hormone in European territories |
|
|
Jun |
Retail pharmacists answer that Hanmi's sales reps are the kindest and the most impressive |
|
|
May |
Hanmi expands the licensing agreement with Merck |
|
|
April |
Hanmi signs a collaboration agreement with Kinex to develop and market a novel anti-cancer drug candidate, KX-01 |
|
|
April |
Esomezol receives IR52 Jang Young-Shil Award from KOITA |
|
|
March |
Hanmi's Amosartan ranked the second highest for detailing drugs |
|
|
February |
Hanmi strengthens R&D with a new external collaboration unit |
|
|
February |
Hanmi's Clopidogrel, approved in European Countries |
|
|
January |
Hanmi`s Esomezol wins IR52 Jang Young-Shil Award |
|
|
January |
A filing letter from FDA for modified Esomeprazole Capsuleb |
|
|
January |
R&D reinforcement with a new external collaboration unit (eR&D) |
